Neurocognitive Battery Feasible in 3-Year-Olds During Leukemia Treatment
WEDNESDAY, Dec. 18, 2024 -- A brief neurocognitive battery is feasible for use in 3-year-olds during acute lymphoblastic leukemia treatment, according to a study published online Dec. 9 in Pediatric Blood & Cancer.
Sameera Ramjan, from Memorial Sloan Kettering Cancer Center in New York City, and colleagues offered patients enrolled in the Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents participation in an optional neurocognitive study assessing longitudinal changes in neurocognitive function. The analysis included 3- and 4-year-old patients enrolled in the study.
The researchers found that 3-year-old patients did not differ from 4-year-olds in terms of their ability to perform or complete the brief Cogstate battery assessing psychomotor function (detection) and attention (identification). These findings persisted at four time-point assessments, through 52 weeks after diagnosis.
"This report demonstrates that computerized testing, such as Cogstate, can be successfully administered to 3-year-old patients who are undergoing treatment for acute lymphoblastic leukemia, thereby capturing serial test data on a vulnerable patient population that, in prior studies, have demonstrated worse neurocognitive deficits," the authors write. "Consequently, changing future study inclusion criteria to include patients diagnosed at the age of 3 years will ultimately serve to improve our understanding of at-risk patients and the neurocognitive trajectory of this age group both during treatment as well as into survivorship, thereby leading to the development of early interventions."
One author disclosed ties to the pharmaceutical industry; two authors disclosed ties to Cogstate.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Cancer Survival Lower in Rural Areas
WEDNESDAY, Oct. 1, 2025 -- Five-year cancer survival rates for each stage of cancer (localized, regional, and distant) is lower in nonmetropolitan areas for Black and White...
Loss of Smell May Linger After COVID-19
WEDNESDAY, Oct. 1, 2025 -- Self-reported change or loss in smell or taste is an accurate signal of verified hyposmia after COVID-19, although there is also a high rate of hyposmia...
Elderly Patients Benefit From Screening Mammography
WEDNESDAY, Oct. 1, 2025 -- Patients with breast cancer diagnosed at 80 years of age or older who received screening mammography present with earlier-stage disease and have better...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.